Trial · NCT04370548
Trial comparisons14
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 14 of 14
Download this page as JSON| Comparison | Source |
|---|---|
| Clindamycin Phosphate Vaginal Gel, 2% vs Placebo Vaginal Gel (Universal HEC Placebo Gel): Number of Patients With Bacteriological Cure at Interim Assessment Visit, Day 7-14 | Trial comparisons |
| Clindamycin Phosphate Vaginal Gel, 2% vs Placebo Vaginal Gel (Universal HEC Placebo Gel): Number of Patients With Bacteriological Cure at Test of Cure Visit, Days 21-30, PP Population | Trial comparisons |
| Clindamycin Phosphate Vaginal Gel, 2% vs Placebo Vaginal Gel (Universal HEC Placebo Gel): Number of Patients With Bacteriological Cure at the TOC Visit (Day 21-30). | Trial comparisons |
| Clindamycin Phosphate Vaginal Gel, 2% vs Placebo Vaginal Gel (Universal HEC Placebo Gel): Number of Patients With Bacteriological Cure, Interim Assessment Visit, Days 7-14, PP Population | Trial comparisons |
| Clindamycin Phosphate Vaginal Gel, 2% vs Placebo Vaginal Gel (Universal HEC Placebo Gel): Number of Patients With Therapeutic Cure at the Interim Assessment Visit (Day 7-14). | Trial comparisons |
| Clindamycin Phosphate Vaginal Gel, 2% vs Placebo Vaginal Gel (Universal HEC Placebo Gel): Number of Patients With Therapeutic Cure at Test of Cure Visit, Days 21-30; PP Population | Trial comparisons |
| Clindamycin Phosphate Vaginal Gel, 2% vs Placebo Vaginal Gel (Universal HEC Placebo Gel): Number of Patients With Clinical Cure at the TOC Visit (Day 21-30). | Trial comparisons |
| Clindamycin Phosphate Vaginal Gel, 2% vs Placebo Vaginal Gel (Universal HEC Placebo Gel): Number of Patients With Therapeutic Cure, Interim Assessment Visit, Days 7-14, PP Population | Trial comparisons |
| Clindamycin Phosphate Vaginal Gel, 2% vs Placebo Vaginal Gel (Universal HEC Placebo Gel): Number of Patients With Therapeutic Cure at the TOC Visit (Day 21-30). | Trial comparisons |
| Clindamycin Phosphate Vaginal Gel, 2% vs Placebo Vaginal Gel (Universal HEC Placebo Gel): Number of Patients With Clinical Cure at the Interim Assessment Visit (Day 7-14). | Trial comparisons |
| Clindamycin Phosphate Vaginal Gel, 2% vs Placebo Vaginal Gel (Universal HEC Placebo Gel): Number of Patients With Clinical Cure at Interim Assessment Visit, Days 7-14, PP Population | Trial comparisons |
| Clindamycin Phosphate Vaginal Gel, 2% vs Placebo Vaginal Gel (Universal HEC Placebo Gel): deaths from any cause | Trial comparisons |
| Clindamycin Phosphate Vaginal Gel, 2% vs Placebo Vaginal Gel (Universal HEC Placebo Gel): Number of Patients With Clinical Cure at the Test of Cure Visit (21-30) | Trial comparisons |
| Clindamycin Phosphate Vaginal Gel, 2% vs Placebo Vaginal Gel (Universal HEC Placebo Gel): serious adverse events | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04370548/comparisons